Prerequisite: None

Kate Mulroney

Senior Director, Advanced Analytics & AI

Novo Nordisk Inc.

This session will include a moderated Q&A featuring questions from the live audience.

“Patient centricity” is a central theme in the pharmaceutical industry in 2025—ensuring patient health and outcomes are optimized, while driving brand performance. The use of AI and real-world data (RWD) in commercial analytics presents significant opportunities for patient centricity but also necessitates robust patient data privacy protections. This presentation will cover Novo Nordisk's program to safeguard patient data in this evolving landscape.

Kate Mulroney will discuss the company’s risk-based governance program, designed for pragmatic implementation and enabling valuable data analysis while upholding stringent governance standards. A core component is a consolidated patient data ecosystem, which leverages advanced patient data tokenization, as well as an overall AI and data governance program. In combination, these programs ensure confidentiality, integrity, and availability, while providing the ability to gain deep patient insights.